Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder
Completed · Phase 2, Phase 3 · NCT05523895
Conditions: Irritability Associated With Autism Spectrum Disorder
At a glance
- Research payments reported, 2025
- $549,163
- U.S. investigators named
- 18
- Sites paid
- 21
- Planned or actual enrollment
- 237
About the trial
- Sponsor
- ACADIA Pharmaceuticals Inc.
- Tested
- Pimavanserin (drug), Placebo (drug)
- Dates
- Started 2022-08-09; completion 2024-09-27
- Results posted
- Yes
6-week, randomized, double-blind, fixed-dose, placebo-controlled, parallel group study in children and adolescents (aged 5 to17 years) with autism spectrum disorder (ASD) with irritability, agitation, or self-injurious behaviors to study the efficacy and safety of pimavanserin
From ClinicalTrials.gov, last updated 2025-08-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Acadia Pharmaceuticals Inc reported $549,163 in research payments for this study in 2025 (57 payments).
Products named: Acp-103
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Raun Melmed, MD Developmental-Behavioral Pediatrics · Scottsdale, AZ
- Elysa J. Marco, M.D. Neurology · San Francisco, CA
- Kevin A. Shapiro, MD, PHD Child Neurology · Pasadena, CA
- Isaac Melamed, M.D. Specialist · Centennial, CO
- Adelaide Robb, MD Neurology · Washington, DC
- Morteza Nadjafi, M.D. Psychiatry · Orlando, FL
- Elias H. Sarkis, MD Child & Adolescent Psychiatry · Gainesville, FL
- Riaz A. Baber, M.D. Psychiatry · Naperville, IL
- Mcleod Gwynette, MD Child & Adolescent Psychiatry · Shreveport, LA
- Ann Childress Child & Adolescent Psychiatry · Las Vegas, NV
- Mark Dibuono, MD Psychiatry · Staten Island, NY
- Diab Almhana, MD Psychiatry · Avon Lake, OH
- Ernest Pedapati, M.D. Child & Adolescent Psychiatry · Cincinnati, OH
- Amanda Bennett, MD Developmental-Behavioral Pediatrics · Philadelphia, PA
- Lawrence D. Ginsberg, M.D. Psychiatry · Houston, TX
- Sejal S. Mehta, M.D. Psychiatry · Plano, TX
- Bradley J. Musser, M.D. Family Medicine · Richardson, TX
- James A. Knutson, M.D. Prescribing Psychologist · Kirkland, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Cortica Inc $131,906
- Southwest Autism Research $62,372
- Childrens Research Institute $55,292
- Core Clinical Research $50,406
- Relaro Medical Trials $48,666
- Anzoni $42,987
- Southwest Autism Research Center $39,160
- Apg Research LLC $17,179
- Children's Hospital of Philadelphia, PA $13,881
- Apg Research $13,511
- Cincinnati Children's Hospital Medical Center, OH $11,700
- Clinical Research of Southern Nevada $11,199
- Richmond Behaivoral Associates $8,786
- Amr Baber Research Group $8,262
- Immunoe Research Centers $6,543
- Red Oak Psychiatry Associates $6,287
- Musc Medical Center, SC $6,226
- Quest Therapeutics of Avon Lake $5,902
- Southwest Autism Research Center $3,583
- Amr Baber Research Group Inc $3,163
- Aim Trials $2,151
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.